Explore

Rapid Read Rapid Read
Illinois Patients Begin Receiving Experimental Pancreatic Cancer Drug

Illinois Patients Begin Receiving Experimental Pancreatic Cancer Drug

Patients in Illinois have started receiving an experimental drug, daraxonrasib, for treating pancreatic cancer. The drug, considered a breakthrough, extends the lives of patients with metastatic pancreatic cancer who have undergone previous treatments. In clinical trials, patients receiving daraxonrasib lived for a median of 13 months compared to six months for those on additional chemotherapy. The drug is not yet FDA-approved but is available under an expanded access program. The program allows eligible patients to receive the drug at no cost, providing hope for those with limited treatment options.
Rapid Read Rapid Read
Scientists Propose Repurposing Glaucoma Drugs to Combat Aggressive Cancers

Scientists Propose Repurposing Glaucoma Drugs to Combat Aggressive Cancers

Researchers at The Institute for Cancer Research have discovered that drugs currently used to treat glaucoma could potentially be repurposed to combat aggressive cancers such as breast cancer, melanoma, and acute myeloid leukemia. The study identified a common molecular target, ROCK, which these cancers rely on to spread and become aggressive. By inhibiting this molecule, the drugs could potentially be used to treat these cancers. The research suggests that these existing drugs, already approved for glaucoma, could be fast-tracked into clinical trials for cancer treatment, potentially reaching patients more quickly. The study also identified specific markers that could help determine which patients might benefit from this treatment.
Rapid Read Rapid Read
Ohio State University Identifies New Target for Glioblastoma Treatment

Ohio State University Identifies New Target for Glioblastoma Treatment

Researchers at The Ohio State University Comprehensive Cancer Center have identified a potential new target for treating glioblastoma, one of the deadliest forms of brain cancer. The study, published in Cancer Letters, highlights the role of the protein SET in making glioblastoma cells more vulnerable to treatment. By suppressing SET, researchers found that tumor formation was prevented in preclinical models. The study also explored the role of PP2A, an enzyme that glioblastoma cells block through proteins like ANP32A, CIP2A, and SET. Blocking these proteins increased the cancer cells' sensitivity to radiation, suggesting a new pathway for drug targeting. The research is still in its early stages and has not yet been tested in human patients.
Rapid Read Rapid Read
Red Devil Chemo: Understanding Doxorubicin's Role in Cancer Treatment

Red Devil Chemo: Understanding Doxorubicin's Role in Cancer Treatment

Red Devil Chemo, commonly known as doxorubicin, is a chemotherapy drug used in the treatment of various cancers, including breast cancer, lymphomas, and sarcomas. Known for its bright red color, doxorubicin is part of the anthracycline group of medicines that work by damaging the DNA of fast-growing cancer cells. While effective, it requires careful monitoring due to potential side effects affecting the blood, heart, digestive system, and skin. The drug is typically administered in cycles with rest periods to allow the body to recover, and it is often used in combination with other chemotherapy drugs to enhance treatment efficacy.
Rapid Read Rapid Read
BC Cancer and UBC Researchers Identify New Hereditary Prostate Cancer Gene

BC Cancer and UBC Researchers Identify New Hereditary Prostate Cancer Gene

Researchers at BC Cancer and the University of British Columbia have discovered a new form of hereditary prostate cancer linked to mutations in the CDK12 gene. This rare genetic mutation can lead to aggressive prostate cancer at a young age. The study analyzed genetic data from over 4,500 individuals with aggressive prostate cancer, identifying five men with inherited CDK12 mutations who developed metastatic cancer between ages 44 and 62. The discovery suggests that CDK12 mutations, previously thought to occur only spontaneously, can be inherited. This finding could lead to enhanced genetic testing and early detection programs for at-risk families.
Rapid Read Rapid Read
FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

FDA Approves Pluvicto for Expanded Use in Metastatic Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved Pluvicto, a radioligand therapy developed by Novartis, for use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). This approval is based on the Phase III PSMAddition trial, which demonstrated that Pluvicto, in combination with standard care, significantly reduces the risk of disease progression or death. The therapy is now available for use across all stages of PSMA-positive metastatic prostate cancer, nearly doubling the eligible patient population. This marks a significant advancement in the treatment landscape for mHSPC, offering a new precision approach for early intervention.
Rapid Read Rapid Read
Dana-Farber Cancer Institute Develops Platform for Discovering Molecular Glue Degraders

Dana-Farber Cancer Institute Develops Platform for Discovering Molecular Glue Degraders

Researchers at the Dana-Farber Cancer Institute have developed a novel platform for discovering molecular glues, which are compounds that can target and degrade disease-associated proteins previously considered undruggable. This platform leverages the ubiquitin-proteasome system to eliminate unwanted proteins by binding them to E3 ligases, which tag them for disposal. The study, published in Nature, highlights the potential of these molecular glues to expand the range of proteins that can be targeted for therapeutic purposes, particularly in cancer treatment. The platform has already led to the discovery of a metabolically activated molecular glue degrader, suggesting that these compounds could be more context-dependent and tunable than previously thought.
Trendline Trendline
Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials
Trendline Trendline
Plus Therapeutics Advances Cancer Treatment with Rhenium Obisbemeda

Plus Therapeutics Advances Cancer Treatment with Rhenium Obisbemeda

Plus Therapeutics Advances Cancer Treatment with Rhenium Obisbemeda
Rapid Read Rapid Read
Roswell Park Study Identifies Protein 'Switch' in Liposarcoma Aggressiveness

Roswell Park Study Identifies Protein 'Switch' in Liposarcoma Aggressiveness

Researchers at Roswell Park Comprehensive Cancer Center have identified a protein 'switch' that determines the aggressiveness of liposarcoma cells. Led by Dr. Blake Wilde, the study reveals that the protein PPAR-gamma influences whether stem-like cells in liposarcoma tumors develop into more aggressive or less aggressive forms. This discovery could lead to new treatment strategies for liposarcoma, a rare cancer that often recurs despite treatment. The research highlights the potential for targeting these stem-like cells to prevent the progression of manageable tumors into more dangerous forms.
Rapid Read Rapid Read
Florida Invests $2 Million in FIU's Personalized Cancer Treatment Program

Florida Invests $2 Million in FIU's Personalized Cancer Treatment Program

The Florida Legislature has allocated $2 million to expand Florida International University's (FIU) Functional Oncology Rapid Cancer Elimination (myFORCE) Program. This initiative, led by Diana Azzam, focuses on personalized cancer treatments by testing FDA-approved drugs on patient-derived tumor cells. The funding will support core operations, expand clinical trials, and position Florida as a leader in precision oncology. The program aims to provide effective treatment options for patients with treatment-resistant cancers.
Trendline Trendline
Cellectis Advances Gene Therapy Trials with FDA Designation for Lasme-cel

Cellectis Advances Gene Therapy Trials with FDA Designation for Lasme-cel

Cellectis Advances Gene Therapy Trials with FDA Designation for Lasme-cel